User menu

High-Dose Methotrexate Seems to Benefit Only to Standard-Risk BCP-ALL Patients with Good Early Response to Chemotherapy: Final Analysis of the FRALLE93B Study

Bibliographic reference Leblanc, Thierry ; Vermylen, Christiane ; Landman-Parker, Judith ; Auclerc, Marie-Francoise ; Desseaux, Krystell ; et. al. High-Dose Methotrexate Seems to Benefit Only to Standard-Risk BCP-ALL Patients with Good Early Response to Chemotherapy: Final Analysis of the FRALLE93B Study.50th Annual Meeting of the American- Society-of-Hematology (San Francisco (Ca), Dec 06-09, 2008). In: Blood, Vol. 112, no. 11, p. 10-10 (2008)
Permanent URL http://hdl.handle.net/2078.1/58810